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The CDK inhibitor p21 (WAF-1/CIP-1/SDI-1) has been implicated in DNA damage-induced p53-mediated G~ 
arrest, as well as in physiological processes, such as cell differentiation and senescence, that do not involve 
p53 function. To determine the impact of p21 on normal development and cell-cycle regulation in vivo, we 
have generated transgenic mice that abundantly express p21 specifically in hepatocytes. During postnatal liver 
development, when transgenic p21 protein becomes detectable, hepatocyte proliferation is inhibited 
dramatically. This disturbance causes a reduction in the overall number of adult hepatocytes, resulting in 
aberrant tissue organization, runted liver and body growth, and increased mortality. The transgenic p21 
protein is associated with most, if not all, of the cyclin D1-CDK4 in liver but not significantly with other 
cyclin/CDK proteins, indicating the importance of cyclin D1-CDK4 function in normal liver development. 
The appearance of large polyploid nuclei in some hepatocytes indicates that p21 may also cause arrest during 
the G2 phase of the cell cycle. Significantly, partial hepatectomy failed to stimulate hepatocytes to proliferate 
in p21 transgenic animals. These results provide the first in vivo evidence that appropriate p21 levels are 
critical in normal development and further implicate p21 in the control of multiple cell-cycle phases. 
[Key Words: Cell cycle; liver development; liver regeneration; CDK inhibitor; p21; growth arrest; trangenic 
mice; cell specificity] 
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Control of cellular proliferation requires a balance be- 
tween positive and negative regulatory pathways. Sev- 
eral experimental approaches suggest that such balance 
is achieved, in part, by regulating the activity of the cy- 
clin-dependent kinases (CDKs) that provide the primary 
control of eukaryotic cell-cycle progression. In mamma- 
lian cells, both CDKs and cyclins constitute multiple 
gene families. Each CDK controls the transition through 
different points of the cell cycle through specific associ- 
ations with the various cyclins. For example, CDKs as- 
sociated with the D- and E-type cyclins appear to control 
the rate of passage through the G1 phase of the cell cycle, 
and perturbations in the levels of these proteins can lead 
to the loss of normal G1 control (Sherr 1994; Hunter and 
Pines 1994). In addition to cyclin activation, CDK activ- 
ity is also regulated by subunit phosphorylation, both 
stimulatory and inhibitory (Solomon 1994; Morgan 
1995). 
3Present address: CATO Research, Durham, North Carolina 27713-2280 
USA. 
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Recent studies have revealed that CDK activity can 
also be negatively regulated by several CDK inhibitors 
(Sherr and Roberts 1995). At least seven CDK inhibitors 
have been identified, and on the basis of homology, these 
currently can be classified into two prototype groups de- 
noted by the first members discovered--p21 and p16 
(Sherr and Roberts 1995). The p16 family currently in- 
cludes four related members: p16 znkaa (also known as 
MTS1, CDK4I; Serrano et al. 1993; Kamb et al. 1994; 
Nobori et al. 1994), p15 xnk4b (also known as MTS2 and 
p14; Guan et al. 1994; Hannon and Beach 1994; Kamb et 
al. 1994), p18 Ink4c (Guan et al. 1994), and p19 tnk4d (Hirai 
et al. 1995; Ming et al. 1995; Guan et al. 1996). The 
proteins of this family bind specifically to CDK4 and 
CDK6, preventing the association of the CDKs with cy- 
clin D (Hirai et al. 1995; Guan et al. 1996). The genes 
that encode two members--p 16 and p 15--are mutated in 
certain human tumors (Kamb et al. 1994; Nobori et al. 
1994; Sherr and Roberts 1995), implicating these CDK 
inhibitors as tumor suppressors. 
The proteins of the p21 family are structurally and 
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functionally distinct from those of the p16 family and 
currently include three members: p21 (also known vari- 
ously as WAF1, SDI1, Cip 1, CAP 20, Picl, and CDKN1; 
E1-Deiry et al. 1993; Harper et al. 1993; Xiong et al. 
1993a; Noda et al. 1994); p27 Kip1 (Polyak et al. 1994; 
Toyoshima and Hunter 1994), and p57 rap2 (Lee et al. 
1995; Matsuoka et al. 1995). These proteins can complex 
with and thereby regulate the activity of a wide range of 
cyclin and CDK enzymes (Sherr and Roberts 1995). In 
addition, p21 binds proliferating cell nuclear antigen 
(PCNA), a processivity factor for DNA polymerase 8, and 
inhibits PCNA-dependent DNA replication in vitro 
(Flores-Rozas et al. 1994; Li et al. 1994; Waga et al. 1994; 
Luo et al. 1995; Chen et al. 1995). Binding of p21 or p27 
to CDK has also been shown to block activating phos- 
phorylation of CDK by CDK-activating kinase (CAK) 
(Kato et al. 1994; Aprelikova et al. 1995). Therefore, p21 
could potentially regulate cell-cycle progression through 
multiple distinct molecular mechanisms. 
Expression of the p21 gene is induced by a wide range 
of cell growth regulatory signals, including DNA damage 
from a p53-dependent mechanism (E1-Deiry et al. 1993; 
Xiong et al. 1993a; Dulic et al. 1994), cellular senescence 
(Noda et al. 1994), and the antiproliferative transforming 
growth factor B (TGF-B; Elbendary et al. 1994; Datto et 
al. 1995; Li et al. 1995). Examination of the expression of 
p21 transcripts in cultured cells and in mice has shown 
a correlation between p21 expression and the withdrawal 
of cells from the division cycle during differentiation of 
a number of cell types (Jiang et al. 1994; Michieli et al. 
1994; Steinman et al. 1994; Guo et al. 1995; Halevy et al. 
1995; Missero et al. 1995; Parker et al. 1995). Such cor- 
relation raises the possibility of a potential role for p21 in 
normal cell differentiation. Mice homozygous for a null 
mutation in the p21 gene, however, developed normally 
and did not demonstrate a predisposition to tumorigen- 
esis, suggesting that p21 is not required for normal dif- 
ferentiation (Deng et al. 1995). The interpretation of the 
knockout experiments, however, was complicated by 
the possibility that p21 function in p21-null mice may be 
compensated by other CDK inhibitors. Additionally, it 
was not possible to assess the pathophysiological conse- 
quence of altered p21 levels in p21-null animals. In vitro 
studies have demonstrated that relative levels of p21 
may be critical in determining the threshold kinase ac- 
tivity of various cyclin-CDK enzymes (Zhang et al. 
1994; Harper et al. 1995), suggesting that appropriate lev- 
els of p21 may be critical in normal cell division and 
animal development. 
The ability to manipulate the levels of transgene ex- 
pression in specific tissues in vivo provides an alterna- 
tive strategy to assess the functional roles of p21 in the 
developing animal. The liver provides an excellent and 
well-characterized experimental system for studying the 
cell-cycle and cellular proliferation and differentiation in 
vivo, in part because of the ability to analyze cell cycle 
regulatory molecules during liver regeneration in re- 
sponse to partial hepatectomy (Lu et al. 1992; Loyer et al. 
1994). In this study we have used a liver-specific pro- 
moter (Yan et al. 1990) to direct selective expression of 
murine p21 to hepatocytes. Using this strategy we have 
effectively created a dominant mutant phenotype for p21 
that facilitates a functional analysis of the cell cycle 
within an otherwise genetically normal animal. 
R e s u l t s  
Targeted expression of p21 in liver 
To elicit deregulated expression of the p21 CDK inhibi- 
tor within the liver of mice, we used transcriptional reg- 
ulatory signals from the liver-specific gene that encodes 
transthyretin {TTR), a serum thyroid hormone carrier 
produced in hepatocytes (Yan et al. 1990}. We showed 
previously that the first exon and intron and a partial 
second exon of a TTR minigene consisting of 3 kb up- 
stream of the RNA start site is expressed consistently to 
very high levels [up to 1.5-fold of the endogenous TTR 
mRNA} in the livers of transgenic mice (Yan et al. 1990). 
The mouse p21 cDNA was cloned after PCR amplifica- 
tion from a mouse fibroblast eDNA library, confirmed by 
sequence analysis, and inserted into the second exon of 
the TTR minigene (Fig. 1A). The 3'-untranslated se- 
quences were replaced with a small fragment from the 
SV40 early region that carries the 3' end RNA processing 
signals. Five founder mice were produced with this 
transgene (Table 1, TgTTRp21-1 through TgTTRp21-5). 
Offspring of each founder mouse were generated and 
examined for transgene expression at the level of RNA, 
protein, or both (Figs. 1B and 2). The tissue distribution 
of transgene expression was characteristic of the TTR 
minigene (Yan et al. 1990). As indicated in Figure IC, the 
RNase protection assay detected transgenic, but not en- 
dogenous, p21 transcripts as well as endogenous TTR 
mRNA, providing an internal standard. Primer extension 
analysis confirmed that the correct transcription start 
site was used (data not shown). Transgene-specific 
mRNA was expressed abundantly in the livers of mice 
from families 1, 3, and 4 and comprised 11.0%-79.0% of 
the endogenous TTR mRNA {Fig. 1B; Table 1). Family 5, 
although not examined for mRNA, also expressed the 
transgene in liver based on protein analysis (see below). 
Mice of the TgTTRp21-2 family expressed only low lev- 
els of transgene mRNA in the liver (<0.1% of endoge- 
nous TTR; Fig. 1B, lane 2). In addition to liver, the TTR 
minigene vector is expressed in brain choroid plexus ep- 
ithelium, but only when present in multiple (6-10) cop- 
ies {Yan et al. 1990}. Only one mouse family, TgTTRp21- 
4, expressed detectable transgenic transcripts in the 
brain (Fig. 1B, lane 6), and none of the families expressed 
detectable p21 protein in this tissue (see below). 
Immunoprecipitation followed by Western blotting 
was used to determine p21 protein levels in various tis- 
sues of transgenic mice relative to normal littermates. A 
representative experiment is shown in Figure 2A. Our 
study, as well as other recent reports (Parker et al. 1995; 
D. Franklin, Y. Li, E. Lee, and Y. Xiong, in prep.), indi- 
cates that in normal, fully differentiated tissues, p21 pro- 
tein levels are very low. Of the nontransgenic tissues we 
examined, only lung expressed detectable p21 (Fig. 2A, 
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Figure 1. TTR p21 transgene and RNA Expression. (A) The upstream 
regulatory region from + 1 to -3  kb is shown by the small open box. 
Large boxes denote exons. (Dark stippled box) TTR exonic sequences; 
(open box) the p21 cDNA; (light stippled box) a small fragment of the 
SV40 early region that harbors the polyadenylation sequence. The 
intron (denoted by a straight line) is the complete TTR first intron. 
Small solid boxes in the upstream region denote the liver-specific en- 
hancers that direct hepatocyte expression in cell culture (Costa et al. 
1986) and in the animal (Yan et al. 1990). The bottom diagram shows the 
portion of the original pTTR1EXV3 vector from which the RNA probe 
(horozontal solid arrow} for RNase protection analysis was derived. The 
mouse p21 cDNA was inserted into the StuI site of the pTTRExV3 vec- 
tor. (B) RNase protection analysis of p21 transcripts. Ten micrograms of 
RNA was subjected to RNase protection analysis as described in Ma- 
terials and methods. Protected transgenic p21 fragments migrate as 
doublet at -310 nucleotides, whereas endogenous TTR fragments mi- 
grate as a doublet at -90 nucleotides. The RNA probe depicted in A 
hybridizes to the regions of the respective transcripts denoted in C. 
This probe does not hybridize to endogenous p21 mRNA. tRNA was 
used as a nonspecific control. Liver RNA from a TgTTR329 transgenic 
mouse {Yan et al. 1990) that harbors the TTR transgene without the 
p21 insert was used as a positive control (vector). 
lane 7). In contrast, the TgTTRp21 transgenic mice con- 
sistently expressed abundant p21 in liver, reflecting the 
specificity of the TTR regulatory signals (Fig. 2A, lane 4, 
and B, lanes 2-6). Also characteristic of the TTR mini- 
gene (Yan et al. 1990), sporadic p21 expression was ob- 
served in the gut of some transgenic mice in one family, 
TgTTRp21-4 (Fig. 2B, lanes 7-12). 
Immunohistochemistry confirmed that p21 was ex- 
pressed widely in transgenic adult liver hepatocytes (Fig. 
3A, arrows in B and D}. Although p21 was observed in 
the nucleus of some cells (Fig. 3A, arrows in B), it was 
more commonly localized in the cytoplasm (Fig. 3A, ar- 
rows in D). The p21 protein was not detectably expressed 
in a population of nonhepatocyte cells, which are abun- 
dant in transgenic livers (Fig. 3B-D, arrowheads; see be- 
low). Endogenous p21 was undetectable in all adult non- 
transgenic livers examined either by immunoprecipita- 
t ion-immunoblott ing (IP-Western) analysis or by 
immunohistochemistry (Figs. 2, A and B, and 3A, inset). 
p21 complexes with cyclin D1/CDK4 in 
transgenic livers 
Current studies suggest that p21 inhibits progression of 
the cell cycle by binding cyclin-CDK complexes with 
sufficient stoichiometry to inactivate the kinase {Harper 
et al. 1993; Xiong et al. 1993a; Zhang et al. 1994; Harper 
et al. 19951. In cultured cells, p21 has been observed to 
complex with all known cyclin-CDK pairs, albeit with 
different affinities {Zhang et al. 1993, 1994). If p21 func- 
tions similarly in vivo, we would expect to find in- 
creased association of p21 with one or more cyclin-CDK 
pairs in transgenic liver extracts. Analysis of such com- 
plexes in mammalian tissues has not been carried out 
previously because of the limited normal expression of 
p21. 
Using a coupled IP-Western assay, we analyzed the 
association of p21 with cyclin and CDK proteins. Total 
cell lysates were prepared from adult liver and immuno- 
precipitated with antibodies specific to different cyclins, 
CDKs, and p21. Immunoprecipitates were resolved by 
SDS-PAGE and immunoblotted with an antibody spe- 
cific to p21 (Fig. 4A, and B, bottom) or with a mixture of 
antibodies to cyclin D1 and CDKs {Fig. 4B, top}. The 
results were the same for all three mouse lines examined 
(TgTTRp21-3 through TgTTRp21-5) and for multiple 
mice'within each line. A significant level of p21 protein 
GENES & DEVELOPMENT 247 
 Cold Spring Harbor Laboratory Press on February 2, 2021 - Published by genesdev.cshlp.orgDownloaded from 
Wu et al. 
Figure 2. p21 protein expression in trans- 
genic and nontransgenic mouse tissues. Ex- 
tracts of indicated tissues were generated, 
and p21 was immunoprecipitated and de- 
tected by Western blotting as described in 
Materials and methods. Mouse p21 ex- 
pressed in bacteria served as a marker 
(B, lane 13). (A) Several tissues from a 
TgTTRp21-5 mouse. Low levels of p21 
were detected in the lung of both the trans- 
genie mouse and its nontransgenic litter- 
mate. Abundant p21 was present in the 
transgenic liver (lane 4) but undetectable in 
nontransgenic liver (A lane 3; B, lane I). (B) 
Liver extracts from several different fami- 
lies of TgTTRp21 mice as well as from sev- 
eral mice within the TgTTRp21-4 lineage 
as indicated, p21 expression was consis- 
tently high in the liver in all transgenic lin- 
eages shown. Expression of p21 in trans- 
genie gut of the TgTTRp21-4 lineage is vari- 
able from mouse to mouse (lanes 10-12). 
All signals are representative of several ex- 
periments with the exception of the liver 
sample from TgTTRp21-3 that showed p21 
levels comparable to that of TgTTRp21-4 in 
other experiments. 
A 
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was detected readi ly in l iver extracts  f rom transgenic,  
but  no t  normal ,  mice  (Fig. 4, A, lanes 1 and 2, and B, 
lanes 1 and 2 ) and was found in complex  w i t h  cycl in  D1 
and CDK 4 (Fig. 4, A, lanes 4 and 6, and B, lanes  2,5, and 
9). Consis tent ly ,  no  p21 was detected in an t i -cyc l in  D1 
or ant i -CDK4 i m m u n o c o m p l e x e s  derived f rom livers of 
Figure 3. Relationship of p21 expression 
to morphological characteristics of the 
liver. Immunostaining for p21 expression 
(red signal) in adult transgenic mouse liv- 
ers is shown in A, B, D, and F. In C and E, 
the sections were stained only with hemo- 
toxylin and eosin. (A,B,D) p21 expression 
in TgTTRp21 liver is widespread and spe- 
cific for hepatocytes. (A1 Large panel shows 
TgTTRp21-3 liver; (inset) nontransgenic 
littermate (magnification, 64x). B and D 
(magnification, 320x) show staining is he- 
patocyte-specific and both cytoplasmic 
and nuclear. Hepatocytes (arrows) in B 
show nuclear staining and some cytoplas- 
mic staining. Predominantly cytoplasmic 
staining, however, is more common (D). 
(C) Similar section (320x} stained with he- 
motoxylin and eosin shows the presence of 
abundant nonhepatocyte cells, which do 
not express p21 (B and D, arrowheads). E 
and F show, respectively, hemotoxylin and 
eosin stained and anti-p21-stained sections 
of a representative regenerative nodule (n) 
present in some TgTTRp21 transgeni¢ 
mouse livers• The boundary of the nodule 
is marked by arrows. Staining for p21 
shows the loss of p21 expression in the 
nodule and retention of expression outside 
the nodule. 
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Figure 4. p21 forms a complex with cyclin 
D 1 and CDK4 in transgenic livers. Liver ex- 
tracts were generated and respective pro- 
teins were immunoprecipitated and sub- 
jected to Western blotting as described in 
Materials and methods. (A) The antibody 
used for Western analysis was specific for 
p21. (B) The top half of the filter was incu- 
bated with antibodies to cyclin D1, CDK2, 
CDK4, and CDK6, and the bottom half was 
incubated with the antibody to p21. Ex- 
tracts were generated from the livers of a 
transgenic mouse and its nontransgenic lit- 
termate. The positions of CDK2, 4, CDK6, 
cyclin D1, and p21 are indicated. Mouse p21 
produced in bacteria serves as a control. 
normal animals (Fig. 4A, lanes 3,5). Reciprocally, poly- 
peptides that comigrate with CDK4 and cyclin D1 were 
detected in anti-p21 immunocomplexes derived from 
livers of transgenic, but not normal, animals (Fig. 4B, 
lanes 2 and 1, respectively). In this and other experi- 
ments, we did not detect p21 in anti-cyclins E, A, D2, 
and B1, CDC2, CDK2, and CDK6 immunocomplexes 
(Fig. 4A). Preferential association of p21 with CDK4-- 
cyclin D1 in liver cells may reflect both expression of 
higher levels of CDK4--cyclin D1 than other cyclin and 
CDK proteins in these cells and high affinity of p21 for 
CDK4--cyclin D1 complexes. 
Both CDK4 and CDK6 were detected readily in trans- 
genic and nontransgenic liver cells, with the level of 
CDK4 higher than that of CDK6 (Fig. 4B, lanes 5-8). 
CDK2 was also consistently present, but at a much 
lower level (Fig. 4B, lanes 3,4). Transgenic expression of 
p21 did not show any significant effect on the level of 
any of these CDK proteins. The level of cyclin D 1 pro- 
tein and its association with CDK4, however, was 
clearly elevated in liver cells derived from transgenic an- 
imals, as determined by both anti-cyclin D1 and anti- 
CDK4 immunoprecipitations (Fig. 4B, lanes 5 and 6, 9 
and 10). These observations provide in vivo evidence 
supporting the notion that p21 can promote the associ- 
ation of cyclin and CDK subunits (Zhang et al. 1994; 
Harper et al. 1995). 
In transgenic livers, an approximately equal amount of 
cyclin D 1 protein was detected in both anti-p21 and anti- 
cyclin D1 immunoprecipitates (Fig. 4B, lanes 2,9). Simi- 
larly, the same amount of CDK4 protein was also de- 
tected in both anti-p21 and anti-CDK4 immunocom- 
plexes (Fig. 4B, lanes 2,5). These results indicate that 
most, if not all, of the cyclin D 1 and CDK4 proteins were 
complexed with p21. This represents a significant depar- 
ture from normal liver, in which neither p21 nor its as- 
sociation with cyclin D1-CDK4 was detected, raising 
the possibility that the function of cyclin D-CDK4 en- 
zyme is likely impaired in the livers of transgenic mice. 
p21 expression interferes with postnatal 
liver development 
Expression of p21 in the livers of transgenic mice was 
clearly detrimental to their postnatal development. A 
summary of the phenotypic abnormalities present in 
these mice is presented in Tables 1 and 2. In each of 
the families highly expressing the p21 transgene 
(TgTTRp21-1, TgTTRp21-3-TgTTRp21-5), liver mass 
was low (49%-62% the mass of normal lit termate livers; 
Table 21. The affected mice also demonstrated stunted 
growth in comparison to their normal littermates {Fig. 
5A, B), possibly related to the failure of liver growth. The 
body weight of affected mice compared with normal lit- 
termates ranged from 50% to 90%. Moreover, mice in  
each of the affected families had a shortened life span, 
generally dying by 2-3 months of age {Fig. 5C). None of 
these effects were observed in control mice expressing 
the TTR vector alone (Yan et al. 1990) nor in mice that 
abundantly expressed a transgenic protein of similar size 
{p53DD) from the same vector {Table 1; T. Bowman, H. 
Symonds, L. Gu, M. Oren, and T. Van Dyke, in prep.). 
Therefore, the liver abnormalities were attributable spe- 
cifically to the effects of p21 and were not the result of 
nonspecific toxicity. 
Histological examination of p21-expressing livers re- 
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Table 1. Summary of TgTTRp21 transgenic mice 
Expression 
Transgenic mRNA 
line cell/tissue a (% endogenous)b protein b 
Cyclin/Cdk 
Phenotype complex 
TgTTR329 hepatocyte 150 N.D. 
(vector) (brain, eye) variable 
(gut) 
TgTTRp21-1 hepatocyte ¢ 18.0 N.D. 
TgTTRp21-2 hepatocyte 0.1 N.D. 
TgTTRp21-3 hepatocyte 11.0 + + 
TgTTRp21-4 hepatocyte 79.0 + + 
(gut) 
(brain) 
TgTTRp21-5 hepatocyte N.D. + + + 
TgTTRDD-113 d hepatocyte <10.0 + + + + + 
(control) (brain) 
normal 
runted (R) N.D. 
lower liver weight (LW) 
hepatocyte deficit (HD)* 
premature death (PD) 
normal N.D. 
R, LW, HD, PD cyclin D1/Cdk4 
R, LW, HD, PD cyclin D1/Cdk4 
R, LW, ND, PD cyclin D1/Cdk4 
normal 
(N.D.) not determined; (R) runted; (LW) lower liver weight; (HD) hepatocyte deficit; (PD) premature death. 
aExpression from the TTR regulatory region is consistently high in liver hepatocytes of most transgenic families and does not depend 
on transgene copy numbers. Expression in brain and eye depends on the presence of multiple copies. Expression in gut occurs only 
within some families and not in all mice within the family (Yan et al. 1990). 
BmRNA and protein levels given only for liver tissues, mRNA levels are relative to endogenous TTR mRNA level. 
CMice of the TgTTR p21-1 family have not been examined by in situ methods, hepatocyte expression is inferred based on expression 
in liver, and a hepatocyte deficit is inferred from low liver weight as occurs in the other families. 
dTruncated form of p53 protein expressed under TTR promoter control (T. Bowman, H. Symonds, L. Gu, M. Oren, and T. Van Dyke, 
in prep.). 
vealed a cel lular  d i s turbance  tha t  resul ted in decreased 
liver mass.  In no rma l  l ivers >25 hepa tocy tes  comprise  
the length  of hepat ic  plates  be tween  each adjacent  portal  
tr iad and central  ve in  (Fig. 6A, B). In the p21 t ransgenic  
mice,  however ,  as few as six hepa tocytes  were conta ined  
in hepat ic  plates  (Fig. 6C). A l though  the precise number  
of hepa tocy tes  in each hepat ic  plate varied, it was con- 
s i s t en t ly  fewer than  normal .  Consequen t ly ,  the  hepato- 
cyte n u m b e r  in all t ransgenic  mice  was d imin i shed  
great ly and average d is tances  separat ing portal  and cen- 
tral hepat ic  veins  were smal l  (Table 2; Fig. 6C). 
In addi t ion  to a reduc t ion  in the n u m b e r  of hepato-  
cytes, t ransgenic  l ivers  also conta ined  an abundance  of 
cells h is to logica l ly  ident i f iable  as oval cells (Fig. 3A; Ta- 
ble 2). Oval  cells are not  ident i f iable  in  no rma l  livers; 
however,  these  cells proliferate under  condi t ions  in  
wh ich  hepa tocytes  are des t royed or are p revented  f rom 
proliferat ing in response to l iver  damage (Fausto 1990). 
Under  exper imenta l  condi t ions,  oval cells can serve as a 
precursor to both hepa tocy tes  and bile duct  ep i the l ia l  
cells (Evarts et al. 1987, 1989). However ,  i t  is no t  k n o w n  
w h e t h e r  they  n o r m a l l y  cons t i tu t e  a s t em cell compart -  
ment .  The  abundance  of these  cells in  p21-express ing 
t ransgenic  l ivers suggests tha t  the  no rma l  response  to 
insuff ic ient  hepa tocy te  numbers ,  t ha t  is, hepa tocy te  pro- 
l iferation, is impaired.  
Table 2. TgTTRp21 liver characteristics 
Portal to central length of Composition d {%) 
Transgenic Liver mass a hepatic plates b Mega-nuclei c 
line (% controls) {% controls) (%) hepatocyte nonhepatocyte 
non-Tg 100.0 100.0-- 16.4 (n = 2) 0.1 (n = 7) 61.9 38.1 (n = 7) 
TgTTRp21-3 61.6 (n = 2) 60.0 +- 13.4 (n = 2) N.D. N.D. N.D. 
TgTTRp21-4 53.9 (n = 11) 94.5 + 28.0 {n = 4) 2.0 (n = 7) 43.5 56.5 (n = 7) 
TgTTRp21-5 48.5 (n = 1) 73.1 -+ 6.8 (n = 1) N.D. N.D. N.D. 
aLiver mass was compared to that of normal littermates, where n (number of mice examined) is > 1 an average is presented. 
bportal to central lengths of hepatic plates were measured with the aid of microscopy. The average of five to eight separate measure- 
ments per liver is presented, where n (the number of animals) is > 1 the average values are presented. 
CThe number of hepatocyte nuclei of normal size and those larger than 20 ~m in diameter were counted in 10 fields, at 50× 
magnification. Values were expressed as a percent and averaged for seven mice. 
dHepatocytes and nonparenchymal cells were counted as in c and expressed as percent of the sum of the two. Values presented 
represent an average of seven individual mice. 
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Figure 5. Phenotype of TgTTR p21 trans- 
genic mice. (A) Representative growth 
curves of transgenic mice and their normal 
littermates for three separate litters from 
three families of mice. Total body weight 
was determined at indicated ages. (B) A 
representative photograph of one such pair 
of mice at 42 days of age. The mouse on the 
left is the nontransgenic littermate of the 
transgenic mouse on the right. Survival 
times are indicated for three TgTTRp21 
families in C. The percent of surviving 
mice is plotted as a function of time. Sur- 
vival time was measured at the time when 
mice were dying and were sacrificed. 
Interestingly, three of eight TgTTRp21 livers exam- 
ined from three distinct families contained nodular foci 
of hepatocytes. Because liver has the capacity to regen- 
erate, these nodules could have resulted from a signal to 
overcome the deficit of hepatocytes. BrdU incorporation 
analysis confirmed that cells within the nodules were 
proliferating (data not shown). However, p21 in suffi- 
cient levels is thought to inhibit the cell cycle (Sherr and 
Roberts 1995). Thus, we determined whether p21 expres- 
sion was sustained in the nodules. Immunohistochemi- 
cal staining indicated that p21 protein was not expressed 
in most cells of the nodular foci (Fig. 3F). A dramatic 
boundary was found between arrested hepatocytes that 
expressed p21 and proliferating cells in the nodules that 
did not express detectable p21 (Fig. 3E, F). This observa- 
tion indicates that high levels of p21 are incompatible 
with hepatocyte proliferation. Furthermore, because 
p21-expressing cells did not inhibit the proliferation of 
adjacent nonexpressing cells, the effect of p21 is cell au- 
tonomous. The hepatocytes in nodules that did not ex- 
press p21 may have resulted from the deletion or inacti- 
vation of the transgene in precursor cells (Sandgren et al. 
1991). 
Finally, an interesting aberration that consistently ap- 
peared in transgenic livers was the presence of hepato- 
cytes with nuclei two to four times the diameter of the 
largest normal nuclei in nontransgenic livers. Moreover, 
hepatocytes with these giant, highly polyploid nuclei 
comprised up to 2% of the hepatocytes in adult trans- 
genic livers (Table 2). The abundant presence of these 
cells could indicate blockage of some cells in G2 or the 
accumulation of senescent cells (see Discussion). 
p21 inhibits proliferation of postnatal hepatocytes 
In cultured cells, high levels of p21 have correlated with 
cell-cycle arrest and, in some cases, apoptosis (El-Deity 
et al. 1994). Furthermore, p53 {an established transcrip- 
tional regulator of p21) is known to induce apoptosis in 
some types of cells (Yonish-Rouach et al. 1991; Shaw et 
al. 1992}. Theoretically, either activity could have 
caused the observed reduction in mature hepatocyte 
numbers observed in TgTTRp21 mice. To determine the 
impact of p21 expression on hepatocytes during devel- 
opment, we analyzed liver samples by in situ detection 
of p21 expression, DNA synthesis, and apoptosis during 
fetal and postnatal development. 
Immunohistochemical detection of p21 showed only 
weak signals of similar magnitude in both TgTTRp21 
transgenic and nontransgenic littermate livers from em- 
bryonic day 13 (El3) of fetal development to birth {data 
not shown). In nontransgenic littermates, the p21 pro- 
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Figure 6. Liver organization is disrupted in transgenic mice. 
Hepatocyte organization in normal liver is depicted in A and 
is shown for a nontransgenic littermate in B. Transgenic 
(TgTTRp21-3) liver is shown in C. Arrows on diagram {A) and 
photomicrographs (hemotoxylin and eosin-stained sections) 
show distances in the hepatic plate between the central vein {cv) 
and the portal triad, including hepatic artery {ha), bile duct (bd), 
and portal vein (pv). Magnification (50x) is the same in B and C. 
[A is modified from Segal et al. (1992).] 
tein was undetectable in postnatal liver from birth to 
adulthood. In contrast, significant levels of p21 appeared 
in the postnatal liver of transgenic animals -15-20  days 
of age and thereafter remained consistently high (data 
not shown). This onset of expression coincided with the 
time at which a discrepancy between transgenic and 
nontransgenic liver mass became evident (2-3 weeks of 
age). 
In correlation with increased p21 expression, histolog- 
ical evidence of liver abnormalities also appeared in 
transgenic animals during postnatal days 15-20. During 
this time, the population of nonhepatocyte cells in- 
creased and the hepatocyte number decreased compared 
to that of normal littermates (Fig. 7A). The decrease in 
hepatocyte number during this postnatal period appeared 
to result from a p21-induced cell-cycle block as evi- 
denced from a dramatic reduction in cells undergoing 
DNA synthesis [Figs. 7B, and 8, A and BI. In the normal 
postnatal liver, a significant number of hepatocytes pro- 
liferate, contributing to the overall growth in the liver 
during this stage of development (Figs. 7B and 8AI (Vassy 
and Kraemer 1993). In contrast, the TgTTRp21 trans- 
genic mice showed a marked reduction in the percentage 
of S-phase hepatocytes beginning around postnatal day 7 
and persisting into the postweaning period (Fig. 7B). Fur- 
thermore, the abnormally abundant oval-like cells, 
which do not express p21 (Fig. 3B, D), proliferated at a 
high rate as indicated by high levels of BrdU incorpora- 
tion into nuclei (Fig. 8B). 
The in situ TUNEL assay for apopotic cells (see Mate- 
rials and methods) was used to determine whether an 
increase in apoptotic death by p21 may also contribute to 
an adult hepatocyte deficit. Hepatocyte apoptosis was 
minimal in both normal and TgTTRp21 mice (data not 
shown), indicating that cell death was not significantly 
induced by p21 expression. Thus, the reduction in hepa- 
tocyte number and resulting pathological aberrations 
observed in TgTTRp21 adult livers can be accounted 
for by a p21-induced inhibition of postnatal hepatocyte 
proliferation. 
p21 halts cell-cycle progression in regenerating liver 
To determine the impact of p21 on cell-cycle progression 
more directly, we experimentally manipulated the hepa- 
tocyte cell cycle by performing partial hepatectomies 
(PHs) on TgTTRp21 transgenic and normal littermate 
mice. Normal adult hepatocytes are quiescent but can be 
induced to proliferate through one to three rounds of cell 
division by partial resection of the liver (Higgins and 
Anderson 1931; Grisham 1962; Bucher 1963). Because 
induction of this cell-cycle activity is parasynchronous, 
hepatocytes can be systematically followed through cell- 
cycle phases. Sham operations and one of three or two of 
three PHs were performed on several transgenic and non- 
transgenic mice of the TgTTRp21-4 lineage. Mice were 
injected with BrdU, and livers were analyzed histologi- 
cally for hepatocyte morphology, DNA synthesis, and 
the presence of mitotic figures at various times postsur- 
gery (Figs. 9 and 10). 
Expression of p21 in transgenic hepatocytes clearly led 
to a block of the cell cycle, whereas hepatocytes of nor- 
mal littermates progressed normally through the first 
mitotic division. As expected, both transgenic and non- 
transgenic hepatocytes were quiescent prior to PH (Fig. 
9A, pairs 3 and 5, before PH). Normal hepatocytes 
reached a peak of DNA synthesis at 36 hr post-PH, 
whereas hepatocyte DNA synthesis was reduced dramat- 
ically (0.5%-14.5% of normal} in livers of four of five 
transgenic mice examined between 24 and 60 hr post-PH 
(Figs. 8, C and D, and 9A). In all animals, BrdU incorpo- 
ration into gut epithelial cells was normal (data not 
shown), providing a control for BrdU injection and up- 
take. Furthermore, because the data in Figure 9A have 
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Figure 7. Postnatal liver development is A 
disrupted in transgenic mice. {A) The 
abundance of hepatocytes and small non- 
hepatocyte cells in normal and transgenic 
litters. Both hepatocytes and nonhepato- 
cyte cells were counted via microscopy. 
An average of counts from 10 fields at 50x 
magnification was taken and values are 
presented as a percent of the sum of the 
two numbers. In normal livers {hatched 
bars), during postnatal liver development, 
hepatocytes are the most abundant popu- 
. 
lation of cells as shown on the left, 
whereas northepatocyte cells are less abun- 
dant as shown on the right. However, in 
transgenic p21 expressing livers (stippled 
bars), hepatocytes constitute a minor cell 
population (left), whereas nonhepatocyte 1-~ 
cells are abundant (right). The increase in 
this population can be accounted for by the 
appearance of cells with oval cell morphol- 
ogy. This situation persists throughout 
postnatal development when p21 expres- 
sion is detected above normal levels (see 
text). (B) BrdU incorporation into hepato- 
cytes was measured on various days of 
postnatal development as described in Ma- 
terials and methods. Hepatocytes of non- 
transgenic littermates (hatched bars) con- 
tinue to proliferate during this time, while 
the labeling index of hepatocytes is re- 
duced in transgenic littermates (stippled 
bars). The light stippled bars denote the 
percentage of hepatocytes incorporating 
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hepatocytes within the same liver. The 
dark stippled bars have been corrected for the low number of hepatocytes present in transgenic livers and represent the percentage of 
BrdU incorporating hepatocytes compared to the number of hepatocytes in the normal littermate of the same age. 
not been corrected for the reduction of overall hepato- 
cyte numbers in p21-expressing livers, these percentages 
underestimate the level of S-phase inhibition. Although 
transgenic animal 5 (48 hr post-PH) showed weaker re- 
duction in S-phase activity {66% of normal}, this did not 
reflect a lag in the peak of DNA synthesis as evidenced 
from the low percentage of S-phase cells {<2.8% of nor- 
mal) at the transgenic 60-hr time point {Fig. 9A). As in 
post-natal livers of young TgTTRp21 mice, most of the 
BrdU incorporation in livers of post-PH transgenic mice 
occurred in the abundant population of oval-like cells 
{Figs. 8D and 10, D and F). Of interest, several "giant" 
highly polyploid hepatocyte nuclei in TgTTRp21 mice 
incorporated BrdU, indicating that these cells might 
have escaped an S-phase block and were arrested in G2 
phase. 
Analysis of mitotic indexes showed that hepatocytes 
in normal mice reached a peak of M-phase activity by 48 
hr after PH (Figs. 9B and 10, A,C, and E). However, the 
TgTTRp21 hepatocytes were not observed to enter M 
phase, even in cases where S-phase activity was substan- 
tial {Fig. 9, mouse 5 and Fig. 10, B,D, and F). These data 
also suggest the possibility that p21-expressing cells may 
be blocked in G2 as well as in G1. Further systematic 
analysis of hepatocyte subpopulations for DNA content 
and cyclin-CDK expression after PH will be required to 
determine whether G~ arrest occurs in a subset of hepa- 
tocytes. The analysis presented here, however, confirms 
that p21 expression impedes cell proliferation and fur- 
ther demonstrates that this effect is dominant even in 
the presence of a powerful mitotic signal. 
D i s c u s s i o n  
This report describes the first in vivo functional analysis 
of a CDK inhibitor by targeted expression. In this study 
we directed expression of p21 specifically to hepatocytes. 
Our results indicate that appropriate levels of p21 are 
critical for normal liver development and demonstrate 
that inappropriate expression leads to severe abnormali- 
ties that can be explained by interference with proper 
control of the hepatocyte cell cycle. In multiple exam- 
ples in this study, expression of the p21 transgene ap- 
pears to severely impair cell proliferation. During the 
postnatal period in transgenic mice, inhibition of hepa- 
tocyte proliferation correlates with the increase of p21 
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Figure 8. DNA synthesis in the livers of 
weanling (A,B) and hepatectomized adult 
(C,D) mice. Dark nuclear staining shows 
the presence of BrdU in newly synthesized 
DNA; animals were injected with BrdU 1 
hr before sacrifice. Arrows show examples 
of DNA synthesis in hepatocyte nuclei; ar- 
rowheads (B and D) show DNA synthesis 
in small nonhepatocyte cells. Sections 
from normal weanling mice (A), and from 
adult mice assayed 36 hr after two-thirds 
PH (C), showed much higher levels of 
DNA synthesis in hepatocyte nuclei than 
did transgenic littermates shown in B and 
D, respectively. Livers from transgenic an- 
imals overexpressing p21 contained few 
hepatocyte nuclei in which DNA was be- 
ing synthesized, but many more small non- 
hepatocyte cells that stained positively for 
DNA synthesis (B,D). Magnification in all 
panels, 50 x. Quantitation of DNA synthe- 
sis in developing animals and in adult he- 
patectomized animals is shown in Figs. 7 
and 9, respectively. 
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expression above normal levels. Such inhibition of cell 
division at this stage can fully account for the deficit of 
hepatocytes observed in adult liver. The impact of p21 
on the cell cycle is even more pronounced in adult ani- 
mals subjected to partial hepatectomy. Hepatocytes 
from hepatectomized transgenic mice display almost 
complete inhibition of induced cell division. Transgenic 
livers also contain increased numbers of proliferating 
oval-like cells, which do not express p21, and occasional 
focal growths of hepatocytes, which have lost expression 
of the p21 transgene. 
Biological function of p21 
We have shown here that enforced p21 expression arrests 
the hepatocyte cell cycle in an otherwise genetically and 
physiologically normal environment. Moreover, this 
function overrides even the powerful mitogenic signals 
that stimulate liver regeneration, p21 was first observed 
to inhibit cell proliferation in cultured cells {E1-Deiry et 
al. 1993; Harper et al. 1993; Xiong et al. 1993a). How- 
ever, its regulation by the tumor suppressor p53 led to 
the speculation that p21 may be the downstream effector 
not only of p53-induced growth arrest but also of p53- 
dependent apoptosis. Consistent with this possibility, 
some studies have correlated increased levels of p21 with 
apoptosis {E1-Deiry et al. 1994). Our studies in liver pro- 
vide evidence that p21 can block the hepatocyte cell cy- 
cle in G] and possibly also in G2 but show no indication 
that p21 triggers apoptosis. Recently, mice homozygous 
for a null mutation in the p21 gene were used to examine 
the known p53-dependent biological activities• Primary 
fibroblasts derived from these mice were partially defec- 
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Figure 9. Cell cycle analysis of p21 expressing livers subse- 
quent PH. PHs were performed as described in Materials and 
methods on TgTTRp21-4 transgenic mice {stippled bars} and 
normal littermates {hatched bars}. The percentage of hepato- 
cytes incorporating BrdU were quantified to determine S-phase 
cells in A. Mitotic figures were assessed morphologically {Fig. 
10) for values in B. Dramatic inhibition of S phase occurs in 
most transgenic mice post-PH and inhibition of entry into M 
phase is indicated for all transgenic mice. One-third of the liver 
was removed for all PHs, with the exception of mouse pair 4, in 
which two-thirds of the liver was removed. 
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Figure 10. Inhibition of cell division by 
p21 expression. Normal littermate 
(A,C,E) and transgenic mouse (B,D,F)liv- 
ers 48 hr post-PH (mouse pair 5, Fig. 9B) 
were analyzed for mitotic figures (by he- 
motoxylin and eosin staining; A,B) and 
DNA synthesis (by BrdU staining; 
C,D,E,F). Mitotic figures are abundant in 
the normal nontransgenic mouse (m, in 
A,C,E). These mitotic figures have incor- 
porated BrdU {C,E), and a number of 
S-phase cells are also present (s, in C,E). 
In the transgenic mice, however, mitotic 
figures are not present. Several aber- 
rantly large nuclei are present {p for 
polyploidy, in B,D,F) and some of these 
nuclei have incorporated low levels of 
BrdU (D). BrdU has readily incorporated 
into the nonhepatocyte cells larrow- 
heads, D,F.I. Original magnification is 
64x in A,B,C,D; 320x in E,F. 
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and intestinal cells were fully competent to undergo 
DNA damage-induced apoptosis, responses that are de- 
fective in p53-null animals (Brugarolas et al. 1995; Deng 
et al. 1995). As with our in vivo results, this study indi- 
cates that p21 functions in p53-dependent cell-cycle ar- 
rest but not in cell death, ruling out the simple notion 
that damaged cells first arrest by a p53-dependent mech- 
anism, and subsequently undergo apoptosis. Down- 
stream of p53, these events appear to involve distinct 
effectors. 
Fibroblasts derived from the p21-null mice are only 
partially defective in Gx arrest compared to p53-null fi- 
broblasts, indicating that p21 is not the only p53-regu- 
lated component of this response (Deng et al. 1995). In 
our studies, however, p21 expression appeared sufficient 
to induce cell-cycle arrest in the absence of p53 regula- 
tion. Such a result indicates that redundancy or compen- 
sation by other factors may occur in p21-null fibroblasts; 
alternatively, cell-type specificity may affect the mech- 
anism of cell-cycle arrest. The possibility for compensa- 
tion underscores the importance of using both dominant 
gain-of-function analysis (as in the current studies) with 
loss-of-function studies (as with null mice) to fully un- 
derstand gene function. Although mice lacking an intact 
p21 gene appear normal (Brugarolas et al. 1995; Deng et 
al. 1995), inappropriate expression of p21 is not well tol- 
erated. The fact that p21 appears to have a role in p53- 
mediated G1 arrest, together with the observation that 
p53, but not p21 (Shiohara et al. 1994), is frequently mu- 
tated in human cancers, may also be an indication that 
there is redundancy in functions downstream of p53. Al- 
ternatively, apoptosis rather than G1 arrest is the critical 
p53 biological activity with an impact on tumorigenesis. 
Further experimentation examining p53-dependent tu- 
mor models in p21-null mice and in mice inappropri- 
ately expressing p21, as described here, will be required 
to directly test these possibilities. 
In cultured cells and in cell-free systems, p21 can com- 
plex with a variety of cyclin-CDK pairs (Xiong et al. 
1993b; Zhang et al. 1993). On the basis of immunochem- 
ical data from this study, p21 was observed predomi- 
nantly in complex with cyclin D 1-CDK4 in transgenic 
adult liver. Previous studies also showed cyclin D1 to be 
present in resting liver and throughout the cell cycle in 
regenerating liver (Lu et al. 1992; Albrecht et al. 1993; 
Koch et al. 1994; Loyer et al. 1994). Thus, the apparent 
specificity of p21 for cyclin D1-CDK4 in this tissue 
could reflect the prevalence of this pair in hepatocytes. 
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Whether differential affinities or specificities also con- 
tribute to the observed selectiveness will require further 
studies using isolated p21-expressing hepatocytes. None- 
theless, the predominant association of p21 with a ma- 
jority of the liver cyclin D1-CDK4 in these mice impli- 
cates cyclin D 1-CDK4 as a key regulator of liver growth 
control. The importance of cyclin D1 in liver growth 
control is underscored by studies implicating amplifica- 
tion and overexpression of the cyclin D1 gene in aggres- 
sive human hepatocellular carcinoma (Nishida et al. 
1994). On the basis of the cell-cycle block observed here 
and the previously established ability of p21 to inhibit 
associated CDK activity, the effect elicited in TgTTRp21 
mice should reflect a specific knockout phenotype for 
both cyclin D 1 and CDK4 in liver. Mice lacking a func- 
tional cyclin D1 gene have been reported recently (Fantl 
et al. 1995; Sicinski et al. 1995). These mice, too, were 
smaller than normal, although specific liver abnormali- 
ties were not reported. On the basis of our studies, fur- 
ther examination of liver organization and cell prolifer- 
ation in cyclin D 1-deficient mice may reveal an abnor- 
mal phenotype. Reported abnormalities in mice lacking 
the cyclin D1 gene occurred in tissues (retina and lactat- 
ing mammary gland) that were not targeted in our study 
of p21. 
Although entry of hepatocytes into S phase is clearly 
inhibited in p21-expressing cells during postnatal and 
posthepatectomy liver growth, there is indirect evidence 
that a fraction of hepatocytes may also be blocked in 
G J M .  Upon synchronous induction of the hepatocyte 
cell cycle after PH, p21-expressing hepatocytes fail to 
enter M phase. This result could be explained by the low 
percentage of cells that make it through S phase, in con- 
junction with the short time of M phase resulting in an 
undetectably low percentage of M-phase cells. However, 
this explanation does not account for the appearance of 
abnormally enlarged nuclei that comprise up to 2% of 
the hepatocytes in transgenic livers (this compares to 
<0.1% in normal livers). In normal livers of young mice, 
hepatocyte ploidy can range from 2N to 8N, with the 
polyploid cells being both bi- and mononuclear. In our 
studies, however, transgenic nuclei were often signifi- 
cantly larger (two to four times the diameter of the larg- 
est normal nuclei) and were shown to synthesize DNA. 
Significantly, in normal rodent and human livers, the 
percentage of polyploid nuclei, as well as the overall 
ploidy, increase with aging (Kudryavtsev et al. 1993). Be- 
cause p21 has been implicated in cellular senescence and 
was originally identified as a senescence factor (Noda et 
al. 1994), it will be of major interest to determine 
whether inappropriately high levels of p21 drive hepato- 
cytes into senescence. Whether the appearance of this 
phenotype results from the ability of p21 to induce a G~ 
block, to drive senescence, or both, will require more 
detailed studies on isolated postnatal hepatocytes. Fur- 
ther studies using the mice described here and similar 
mice with an inducible transgene should help define the 
role of p21 in senescence and determine the extent to 
which the observed phenotypes may also reflect a role 
for p21 in the differentiation process. 
Hepatocyte differentiation, liver development, 
and regeneration 
The TgTTRp21 mice may provide an important model 
for the study of liver growth and development. Nor- 
mally, during the postnatal period, hepatocytes continue 
to proliferate and undergo functional and structural 
changes leading to their terminally differentiated adult 
configuration. The hepatocytes become functionally het- 
erogeneous, with distinguishable zones occurring along 
the tract from portal to central veins. These hepatocytes 
display both ultrastructural and metabolic differences, 
and express distinct subsets of liver-specific gene prod- 
ucts (Gumucio 1989; Jungermann 1995). The period 
from birth to weaning is critical in the establishment of 
liver organization and hepatocellular function. In p21- 
expressing livers, premature cessation of the hepatocyte 
cell cycle clearly results in aberrant liver organization. 
As shown in this report, the major effect is the reduction 
in the number of mature hepatocytes. However, it is not 
clear whether this signal, which overrides normal prolif- 
erative signals, also aberrantly contributes to the termi- 
nal differentiation of hepatocytes. 
M a t e r i a l s  and  m e t h o d s  
Cloning of murine p21 cDNA and construction of transgene 
PCR primers were designed (sequences 5'-AGGATGGC- 
CAATCCTGGTGATGTCCG-3' and 5'-AGGATCCAAGCT- 
TCAGGGTTTTCTCTTGCAG-3') to clone the coding se- 
quence of the p21 cDNA from a murine fibroblast cDNA library 
in ~gt 10 {gift of K. Suzuki, University of North Carolina, Chapel 
Hill). The 5' primer used in the amplification contained a sin- 
gle-base-pair mutation (underlined) changing nucleotide 4 from 
T to G to introduce a NcoI site at the 5' end of the eDNA. This 
mutation changed serine 2 to alanine. This mutation does not 
affect the in vitro or in vivo activity of p21 {this study; Xiong et 
al. 1993a; data not shown). 
The p21 PCR product was digested with HindIU, blunt-ended 
with Klenow polymerase, and cloned into the unique StuI site of 
the pTTR1ExV3 vector {Fig. 1A; see below). The resulting clone, 
pTTREXV3-mp21, was sequenced at the University of North 
Carolina Automated DNA Sequencing Facility on a model 
373A DNA Sequencer (Applied Biosystems) using the Taq 
DyeDeoxy Terminator Cycle Sequencing Kit (Applied Biosys- 
terns). The coding sequence is identical to a murine p21 clone 
identified by Huppi et al. (1994) in a comparative sequence anal- 
ysis of murine p21 cDNAs. 
The pTTR1ExV3 expression vector contains transcriptional 
regulatory sequences from the routine TTR gene consisting of 3 
kb of upstream sequence, the first exon and intron, and much of 
the second exon. pTTR1ExV3 was derived from pTTR1 {Costa 
et al. 1986, 1988) using site-directed mutagenesis to remove two 
ATG start codons (one in each exon) and to introduce cloning 
sites. Briefly, pTTR1ExV3 was constructed by cloning the SacI- 
HindIII fragment of pTTR1 into the PTZ18U phagemid vector, 
followed by removal of the BamHI site of the pTTR1 polylinker 
by SmaI-SalI digestion, Klenow blunting of the SalI site, reli- 
gation, and site-directed mutagenesis of the resulting subclone 
to mutate the ATG in the first exon creating a unique NruI site 
and to introduce a StuI site in place of the ATG 12 bases into the 
second exon. The pTTR1 transgene is expressed consistently in 
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liver hepatocytes as well as in the brain choroid plexus epithe- 
lium when present in many copies (Yan et al. 1990). 
For p21 expression in bacteria, pBluescript KS( + )-rap21 {con- 
taining the p21 eDNA PCR product described above) was di- 
gested with NcoI and BamHI and the resulting p21-encoding 
fragment was cloned into the bacterial expression vector 
pET21d(+) {Novagen). The control p21 protein was prepared by 
induction of pET21d-mp21 expression in bacteria with 0.2 mM 
IPTG followed by harvest of the cells 3--5 hr later, sonication in 
lysis buffer, and clarification by centrifugation. 
Production and screening of transgenic mice 
Plasmid pTTR-mp21 was digested with HindIII to generate a 
4.9-kb transgene fragment (Fig. 1A), which was isolated by gel 
electrophoresis, purified, and injected into (B6D2F1XB6D2F1) 
fertilized eggs as described previously (Yan et al. 1990). Founder 
mice and their offspring were screened using a PCR assay spe- 
cific for the transgene; the 5' primer (5'-AAAGTCCTGGAT- 
GCTGTCCGAG-3') hybridizes to the second TTR exon, and 
the 3' primer (5'-CAGACATGATAAGATACATTGATG-3') 
hybridizes to the SV40 3' tag. DNA was isolated from tail or toe 
samples as described previously (Yan et al. 1990). 
RNA isolation and analysis 
Total cellular RNA was isolated from tissues using the RNAzol 
method as suggested by the manufacturer (Cinna/Biotecx, 
Friendswood, TX). Nuclease protection analysis of transgenic 
transcripts was carried out as described previously (Yah et al. 
1990) except that the incubation temperature was increased 
from 32°C to 37°C and the digests were electrophoresed in a 6% 
polyacrylamide gel. The gels were dried and exposed to Kodak 
XAR-5 film (1-7 days) with an intensifying screen. Quantitation 
of expression levels was determined utilizing a Phosphorimager 
(Molecular Dynamics) and calculating the transgenic transcript 
signal compared to that from endogenous TTR transcripts in the 
same lane as described previously (Yan et al. 1990). Levels given 
in Table 1 are the average of values obtained in two to four 
assays for a single mouse of each lineage. 
Primer extension analysis to determine the 5' start site of the 
transgenic RNA was performed by the addition of 10 ~g of liver 
RNA to a reaction mixture containing 5 mM MgC12, 1 mM 
dATP, 1 rnM dGTP, 1 mM dTTP, 1 x PCR buffer II, 1 unit of 
RNase inhibitor, 2.5 units of murine leukemia virus (MuLV) 
reverse transcriptase (Perkin Elmer), 100 ng of a mouse p21- 
specific primer (5'-CGGAACAGGTCGGACATCACC-3'), and 
10 ~Ci of 32p-labeled dCTP (NEN-Dupont) in 20 ~1 total vol- 
ume. The reaction was incubated at 42°C for 15 min, 99°C for 5 
rain, and 5°C for 5 min, in a Perkin Elmer 9600 thermocycler. 
After incubation, the reactions were extracted once with phe- 
nol/chloroform and precipitated with 0.1 volume of 3M NaOAc 
and two volumes of 100% ethanol. The pellet was then resus- 
pended in 5 ~1 of formamide loading buffer (98% formamide, 
1% bromophenol blue, 1% xylene cyanol) and electrophoresed 
in a 6% polyacrylamide gel. 
IP-Western analysis 
IP-Westem analysis was performed as described previously (Sy- 
monds et al. 1993; Jenkins and Xiong 1995). Briefly, tissue ly- 
sates were prepared by homogenization of tissues (fresh or fro- 
zen at -80°C) in lysis buffer [50 mM Tris-C1 (pH 7.5), 1 mM 
NaaVO4, 150 mM NaC1, 50 mM NaF, 1 mM DTT, 0.5% NP-40] 
with protease inhibitors (Jenkins and Xiong 1995) at 4°C, fol- 
lowed by sonication. Lysates were cleared and IP-Westem anal- 
ysis carried out as described (Jenkins and Xiong 1995). Lysate 
containing 5 mg of protein was used for each assay. Antibody 
amounts were 0.5 ~g (Santa Cruz Biotechnology antibodies), 1 ~1 
of affinity-purified antibody or 1-2 ~1 of crude rabbit serum (see 
below). Proteins were resolved in SDS-polyacrylamide gels 
(15% acrylamide) and transferred to Hybond-ECL nitrocellu- 
lose membranes (Amersham) in a Bio-Rad semidry electroblot- 
ring apparatus. Blots were blocked in blocking buffer [5% nonfat 
dry milk in PBST (PBS at PH 7.4, 0.1% Tween 20)] for 1 hr, 
incubated 2 hr to overnight at 25°C in primary antibody, diluted 
1:5000 in blocking buffer, and then 1 hr with horseradish per- 
oxidase (HRP}-conjugated goat anti-rabbit secondary antibody 
(ZYMED), diluted 1:5000 in blocking buffer. Proteins were de- 
tected with ECL detection reagents (Amersham). 
Antibodies 
Antibodies specific for p21 (C-19, SC-397), CDK4 (C-22, SC- 
260}, CDK6 (C-21, SC-177), cyclin D2 (C17, SC-181), and cyclIn 
E (M-20, SC-481) were from Santa Cruz Biotechnology, Inc. Rab- 
bit sera raised against human CDK2, cyclin A, and cyclin B1 
have been described previously (Xiong et al. 1993a). Rabbit sera 
specific for mouse cyclin D1, cyclin D2, or cyclin D3 were the 
generous gifts of C. Sherr (St. Jude's Children's Hospital, Mem- 
phis, TN). 
Histology and Immunohistochemistry 
Tissues were routinely fixed in 10% buffered formalin (Sigma) 
and embedded in paraffin. For histology, sections (3-8 ~m) were 
stained with hemotoxylin and eosin. For immunohistochemis- 
try, sections were deparaffinzied by two 5-min incubations in 
Hemo-De (Fisher), followed by several changes of ethanol 
(100%, 95%, 70%, and 35%) and rehydration in PBS. For p21 
immunostaining, sections were blocked in 5% normal goat se- 
rum (NGS) in PBS for 30 min and then incubated at 4°C over- 
night with anti-p21 antibody (1:50 in PBS containing 5% NGS; 
Santa Cruz Biotechnology, Inc.). For BrdU assays, sections were 
incubated in 2 N HC1 for 30 rain at 25°C and washed several 
times with PBS. After blocking in 5% horse serum, sections 
were incubated with anti-BrdU antibody (Amersham Cell Pro- 
liferation Kit) for 1-2 hr at 25°C. After three washes in PBS, 
sections were incubated in biotin-conjugated secondary anti- 
body (1:350 in PBS, 2% NGS, Vector Laboratories) for 30 min at 
25°C. Sections were then washed twice with TS buffer [50 mM 
Tris-HC1 (pH 7.6), 150 mM NaC1, 0.1% Tween 20], incubated for 
30 rain in the ABC-AP detection reagent (Vector Laboratories), 
washed twice in TS buffer, incubated for 30 min in alkaline 
phosphate substrate (Vector Laboratories), and washed several 
times with dH20 before counterstaining with hematoxylin, de- 
hydrating by graded ethanol washes, and two changes in Hemo- 
De and mounting. 
BrdU labeling and partial hepatectomy 
For routine BrdU labeling, animals were injected intraperito- 
neally with labeling reagent containing 5-bromo-2'-deoxyur- 
dine (BrdU, Amersham Life Science; 0.03 rag/gram body 
weight) and were sacrificed by CO2 asphyxiation 1 or 2 hr later. 
PH was performed according to the method of Nognchi et al. 
(1991). Surgery was performed under avertin anesthesia. The 
abdominal cavity was entered through a transverse skin inci- 
sion that was placed bilaterally just below and parallel to the rib 
section. The large left lateral lobe (1/3) or additionally the right 
lateral lobe (2/3) were ligated and removed. After 23, 35, 47, or 
59 hr, animals were injected with BrdU and sacrificed 1 hr later 
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as described above. Control animals (before PH) were injected 
with BrdU intraperitoneally 1 hr before surgery. 
In situ detection of apoptosis 
Formalin fixed paraffin-embedded liver sections (7 ~m) were 
deparaffinized in xylene and rehydrated through graded etha- 
nols. The TUNEL assay (Gavrieli et al. 1992) was performed as 
described previously (Symonds et al. 1994) using the Apoptag in 
situ apoptosis kit (Oncor). DNA ends were tagged in situ with 
digoxygenin--dNTP using terminal deoxytransferase. Apoptotic 
cells (which had undergone extensive DNA fragmentation) 
were then detected with anti-digoxigenin HRP (Oncor) for 30 
rain at 25°C. Slides were washed with PBS (4 x 5 rain) and incu- 
bated with 0.05% DAB (Sigma) for 2.5 rain at 25°C. 
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Note  added in proof 
de Nooij and Hariharan (Science 270: 983-985) recently ex- 
pressed human p21 in the developing eye of Drosophila mela- 
nogaster with results similar to those described here. Expres- 
sion of p21 inhibited proliferation (but not differentiation) and 
resulted in fewer cells than normal. 
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